Literature DB >> 15059606

The activities of cyclin D1 that drive tumorigenesis.

Mark E Ewen1, Justin Lamb.   

Abstract

The proto-oncogene cyclin D1 has been implicated in the genesis of a large proportion of human tumors from diverse histological origins. It has long been assumed that the action of cyclin D1, as an activator of cdk4 and cdk6 and leading to progression through the G1 phase of the cell cycle, underlies its pathological activity. But, more recently, analyses of the patterns of gene expression in human cancer have revealed a previously unappreciated mechanism of action for cyclin D1, suggesting that both cdk-dependent and cdk-independent activities might contribute to tumorigenesis. The development of therapeutics designed to target the aberrant activity of cyclin D1 in human cancers will rely upon an intimate molecular understanding of these distinct mechanisms of actions and their relative importance. Here, we describe the known functions of the cyclin D1 oncogene and delineate the evidence that cdk-independent actions are important for cyclin D1-mediated oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059606     DOI: 10.1016/j.molmed.2004.02.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  54 in total

Review 1.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

2.  The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines.

Authors:  John P Alao; Simon C Gamble; Alexandra V Stavropoulou; Karen M Pomeranz; Eric W-F Lam; R Charles Coombes; David M Vigushin
Journal:  Mol Cancer       Date:  2006-02-17       Impact factor: 27.401

Review 3.  Alveolar and lactogenic differentiation.

Authors:  Cathrin Brisken; Renuga Devi Rajaram
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-10       Impact factor: 2.673

4.  IQGAP1 regulates cell proliferation through a novel CDC42-mTOR pathway.

Authors:  Jian-Bin Wang; Robert Sonn; Yemmsrach K Tekletsadik; Daniel Samorodnitsky; Mahasin A Osman
Journal:  J Cell Sci       Date:  2009-05-19       Impact factor: 5.285

5.  Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1-oxide-induced dysplasia and neoplasia in murine squamous oral epithelium.

Authors:  Jonathan F Wilkey; Glenn Buchberger; Kirsten Saucier; Salony M Patel; Ellen Eisenberg; Hiroshi Nakagawa; Carmen Z Michaylira; Anil K Rustgi; Sanjay M Mallya
Journal:  Mol Carcinog       Date:  2009-09       Impact factor: 4.784

6.  Competitive nuclear export of cyclin D1 and Hic-5 regulates anchorage dependence of cell growth and survival.

Authors:  Kazunori Mori; Etsuko Hirao; Yosuke Toya; Yukiko Oshima; Fumihiro Ishikawa; Kiyoshi Nose; Motoko Shibanuma
Journal:  Mol Biol Cell       Date:  2008-10-22       Impact factor: 4.138

7.  The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.

Authors:  Na Zhan; Adeola Adebayo Michael; Kaiyuan Wu; Gang Zeng; Aaron Bell; Junyan Tao; Satdarshan P Monga
Journal:  Gene Expr       Date:  2018-02-06

8.  Cyclin D1 and cyclin D-dependent kinases enhance oral keratinocyte proliferation but do not block keratinocyte differentiation.

Authors:  Michael Woods; Rima Pant; Sanjay M Mallya
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

Review 9.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

10.  Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.

Authors:  M J Schiewer; L M Morey; C J Burd; Y Liu; D E Merry; S-M Ho; K E Knudsen
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.